Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 3, Issue 11, 2008, Pages 1293-1300

  Gadgeel, Shirish M ^a,d   Wozniak, Antoinette ^a   Ruckdeschel, John C ^a   Heilbrun, Lance K ^a   Venkatramanamoorthy, Raghu ^a   Chaplen, Ruth A ^a   Kraut, Michael J ^a,b   Kalemkerian, Gregory P ^c  

^a WAYNE STATE UNIVERSITY   (United States)

^b PROVIDENCE HOSPITAL   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d 4 HWCRC ^*  (United States)

Author keywords

Celecoxib; COX 2; Docetaxel; Elderly; Nonsmall cell lung cancer; PS2

Indexed keywords

CELECOXIB; DEXAMETHASONE; DOCETAXEL; NONSTEROID ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE; TAXOID;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTERY THROMBOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; FATIGUE; FEMALE; HEART INFARCTION; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT FAILURE; VEIN THROMBOSIS; VOMITING; LUNG TUMOR; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PYRAZOLES; SULFONAMIDES; SURVIVAL RATE; TAXOIDS;

EID: 58949100556     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31818b194e     Document Type: Article

References (56)

1. Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of Cancer, 1975-2002, featuring population trends in cancer treatment. J Natl Cancer Inst 2005;97:1407-1427.
2. Schiller J, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
3. Yancik R. Population aging and cancer: a cross-national concern. Cancer J 2005;11:437-441.
4. Havlik RJ, Yancik R, Long S, et al. The National Cancer Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly. Cancer 1994; 74:(7 Suppl)2101-2106.
5. Repetto L, Balducci L. A case for geriatric oncology. Lancet Oncol 2002;3:289-297.
6. Di Maio M, Perrone F, Gallo C, et al. Supportive care in patients with advanced non-small-cell lung Cancer. Br J Cancer 2003;89:1013-1021.
7. Langer CJ, Vangel M, Schiller J, et al. Age-specific subanalysis of ECOG 1594: Fit elderly patients (70-80 yrs) with NSCLC do as well as younger pts (<70). Proc Am Soc Clin Oncol 2003;22:639 (abstract 2571).
8. Belani CP, Fossella FV. Phase III study (TAX 326) of docetaxel-cisplatin and docetaxel-carboplatin versus vinorelbine-cisplatin for the first-line treatment of advanced/metastatic non-small cell lung cancer: analyses in elderly patients. Lung Cancer 2003;41:S18 (Suppl 2).
9. Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non-small cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991;9:1618-1626.
10. Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small cell lung cncer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1986;4:702-709.
11. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061-2067.
12. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003;21: 1383-1389.
13. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362-372.
14. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable Non-small cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353.
15. Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 1991;9:1618-1626.
16. Paesmans M, Sculier JP, Libert P, et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung cancer Working Party. J Clin Oncol 1995;13:1221-1230.
17. Sweeney C, Zhu J, Sandler AB, et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group study 1594: a phase III trial in patients with metastatic non-small cell lung carcinoma. Cancer 2001;92:2639-2647.
18. Kosmidis PA, Dimopoulos MA, Syrigos K, et al. Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group. J Thorac Oncol 2007;2:135-140.
19. Lilenbaum R, Herndon JE, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 2005;23:190-196.
20. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular and molecular biology. Annu Rev Biochem 2000;69:145-182.
21. Taketo M. Cyclo-oxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 1998;90:1529-1536.
22. DeWitt DL. Prostaglandin endoperoxide synthase: regulation of enzyme expression. Biochim Biophys Acta 1991;1083:121-134.
23. Subbaramaiah K, Telang N, Ramonetti JT, et al. Transcription of cyclooxygenase 2 is enhanced in transformed mammary epithelial cells. Cancer Res 1996;56:4424-4429.
24. Sheng H, Shao J, Morrow JD, et al. Modulation of apoptosis and Bcl2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998;58:362-366.
25. Sheng H, Shao J, Washington MK, et al. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001; 276:18075-18081.
26. Goodwin JS, Ceuppens J. Regulation of immune responses by prostaglandins. J Clin Immunol 1983;3:295-315.
27. Tsuji M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogen-esis induced by colon cancer cells. Cell 1998;93:705-716.
28. Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxy- genase 2 occurs frequently in human cancers, specifically in adenocar-cinomas. Cancer Res 1998;58:3761-3764.
29. Wolff H, Saukkonen K, Antilla S, et al. Expression of cyclooxygenase in human lung carcinoma. Cancer Res 1998;58:4997-5001.
30. Hida T, Kozaki K, Muramatsu H, et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000;6:2006- 2011.
31. Subbaramaiah K, Marmo TP, Dixon DA, et al. Regulation of cycloox-genase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR. J Biol Chem 2003;278:37637-37647.
32. Altorki NK, Port JL, Zhang F, et al. Chemotherapy induces the expression of cyclooxygenase-2 in non-small cell lung cancer. Clin Cancer Res 2005;11:4191-4197.
33. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952.
34. Hainsworth JD, Burris HA, Litchy S, et al. Weekly docetaxel in the treatment of elderly patients with advanced non-small cell lung carcinoma. A Minnie Pearl cancer Research Network Phase II Trial. Cancer 2000;89:328-333.
35. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
36. Simon R. Optimal Two-Stage designs for phase II clinical trials. Controlled Clinical Trials 1989;10:1-10.
37. Casella G. Refining binomial confidence intervals. Can J Stat 1986;14: 113-129.
38. Mehta C, Patel N. StatXact 6: statistical software for exact nonparamet-ric inference, user manual. Cambridge, MA: Cytel Software Corporation, 2003. Pp. 1-29.
39. Lee E. Statistical Methods for Survival Data Analysis, 3rd Ed. New York, NY: Wiley & Sons Inc., 2003. Pp. 76-91.
40. Hesketh PJ, Chansky K, Lau DH, et al. Sequential vinorelbine and docetaxel in advanced non-small cell lung cancer patients age 70 and older and/or with a performance status of 2: a phase II trial of the Southwest Oncology Group (S0027). J Thorac Oncol 2006;1:537-544.
41. Hainsworth JD, Spigel DR, Farley C, et al. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced non-small cell lung cancer: a randomized phase 3 trial of the Minnie Pearl cancer Research Network. cancer 2007;110:2027-2034.
42. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorel-bine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21:3016-3024.
43. Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small- cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006;24:3657-3663.
44. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-20103.
45. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-2362.
46. Lilenbaum R, Rubin M, Samuel J, et al. A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer. J Thorac Oncol 2007;2:306-311.
47. Maione P, Perone F, Gallo C, et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol 2005;23:6865-6872.
48. Langer C, Li S, Schiller J, et al. Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599. J Clin Oncol 2007;25:418-423.
49. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-884.
50. Arber N, Eagle CJ, Spicak J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-895.
51. Csiki I, Morrow JD, Sandler A, et al. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel. Clin Cancer Res 2005;11:6634-6640.
52. Gadgeel SM, Thatai L, Kraut M, et al. Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy. Proc Am Soc Clin Oncol 2003;22: abstract 2749.
53. El-Rayes BF, Zalupski MM, Shields AF, et al. A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer. Invest New Drugs 2005;23:583-590.
54. Lilenbaum R, Socinski MA, Altorki NK, et al. Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer. J Clin Oncol 2006;24:4825-4832.
55. Edelman MJ, Watson DM, Wang X, et al. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy-Cancer and Leukemia Group B Trial 30203. J Clin Oncol 2008;26:848-855.
56. Csiki I, Johnson DH. Did targeted therapy fail cyclooxygenase too? J Clin Oncol 2006;24:4798-4800.